Clinical Trial Update: Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the safety and immunogenicity of a single-dose Choleragarde cholera vaccine in HIV-seropositive adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholera
• Diarrhea
• Vibrio Infections

Drugs mentioned

• Choleragarde

Snippet

Sponsor: International Vaccine Institute | Conditions: Cholera, Vibrio Infections | Phase 2 | Status: COMPLETED